- Home
- ITOS vs AURA Comparison
ITOS vs AURA Comparison
Compare ITOS & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITOS
- AURA
- Stock Information
- Founded
- ITOS 2011
- AURA 2007
- Country
- ITOS United States
- AURA United States
- Employees
- ITOS N/A
- AURA N/A
- Industry
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- ITOS Health Care
- AURA Health Care
- Exchange
- ITOS Nasdaq
- AURA Nasdaq
- Market Cap
- ITOS 381.2M
- AURA 396.8M
- IPO Year
- ITOS 2020
- AURA 2021
- Fundamental
- Price
- ITOS $10.18
- AURA $6.56
- Analyst Decision
- ITOS Hold
- AURA Strong Buy
- Analyst Count
- ITOS 6
- AURA 6
- Target Price
- ITOS $10.60
- AURA $22.33
- AVG Volume (30 Days)
- ITOS 911.6K
- AURA 239.4K
- Earning Date
- ITOS 08-07-2025
- AURA 08-07-2025
- Dividend Yield
- ITOS N/A
- AURA N/A
- EPS Growth
- ITOS N/A
- AURA N/A
- EPS
- ITOS N/A
- AURA N/A
- Revenue
- ITOS $35,000,000.00
- AURA N/A
- Revenue This Year
- ITOS N/A
- AURA N/A
- Revenue Next Year
- ITOS N/A
- AURA N/A
- P/E Ratio
- ITOS N/A
- AURA N/A
- Revenue Growth
- ITOS 177.89
- AURA N/A
- 52 Week Low
- ITOS $4.80
- AURA $4.35
- 52 Week High
- ITOS $18.13
- AURA $12.38
- Technical
- Relative Strength Index (RSI)
- ITOS 67.57
- AURA 57.25
- Support Level
- ITOS $9.95
- AURA $6.06
- Resistance Level
- ITOS $10.20
- AURA $6.68
- Average True Range (ATR)
- ITOS 0.15
- AURA 0.34
- MACD
- ITOS -0.09
- AURA -0.01
- Stochastic Oscillator
- ITOS 90.00
- AURA 80.00
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.